<DOC>
	<DOCNO>NCT00290719</DOCNO>
	<brief_summary>RATIONALE : Gefitinib may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , cisplatin irinotecan , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving gefitinib together chemotherapy radiation therapy surgery may make tumor small reduce amount normal tissue need remove . PURPOSE : This phase I/II trial study side effect gefitinib give together cisplatin , irinotecan , radiation therapy surgery see well work treat patient esophageal cancer gastroesophageal junction cancer remove surgery .</brief_summary>
	<brief_title>Gefitinib , Cisplatin , Irinotecan , Radiation Therapy Before Surgery Treating Patients With Esophageal Cancer Gastroesophageal Junction Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate pathologic response ( complete partial ) patient resectable esophageal gastroesophageal junction cancer treat neoadjuvant gefitinib , cisplatin , irinotecan hydrochloride , radiotherapy follow surgical resection . Secondary - Assess safety toxicity regimen patient . - Evaluate objective tumor response patient treat regimen . - Determine rate complete resection patient treat regimen . - Determine surgical morbidity mortality patient treat regimen . OUTLINE : This open-label study . - Induction phase : Patients receive oral gefitinib daily day 1-14 . Patients stable respond disease proceed neoadjuvant chemoradiotherapy . - Neoadjuvant chemoradiotherapy : Patients receive gefitinib induction phase begin week 4 continue last day radiotherapy . Patients also receive cisplatin IV 1 hour irinotecan hydrochloride IV 30 minute day 22 , 29 , 43 , 50 undergo radiotherapy daily , 5 day week , 5 week ( total 25 dos ) . - Surgery : Within 4-8 week completion neoadjuvant chemoradiotherapy , patient stable respond disease undergo esophagectomy lymph node dissection . Patients progressive unresectable disease remove study . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma ( AC ) squamous cell carcinoma esophagus AC gastroesophageal junction allow Tumor must consider surgically resectable ( T13 , NX ) No earlystage cancer ( T1 , N0 ) The following lymph node ( LN ) criterion consider acceptable : Regional thoracic LN metastasis ( N1 ) LN metastases level 15 20 measure ≤ 1.5 cm CT scan Supraclavicular LN palpable clinical examination measure ≤ 1.5 cm CT scan No distant metastasis ( M0 ) PATIENT CHARACTERISTICS : Platelet count ≥ 100,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Hemoglobin ≥ 9.0 g/dL Creatinine clearance ≥ 50 mL/min Creatinine serum level ≤ CTC grade 2 Bilirubin ≤ 2 time upper limit normal ( ULN ) AST &lt; 3 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment No known severe hypersensitivity gefitinib excipients No evidence ( except asymptomatic chronic stable radiographic change ) clinically active interstitial lung disease No pulmonary fibrosis , Gilbert 's disease , uncontrolled diabetes mellitus , unstable angina No New York Heart Association class III IV heart disease No concurrent malignancy malignancy diagnose within past 5 year except basal cell carcinoma carcinoma situ cervix No serious active uncontrolled infection , systemic disease , psychiatric illness , medical condition would preclude study participation No evidence significant clinical disorder laboratory find would preclude study participation PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy esophageal cancer No prior radiotherapy would overlap study treatment field Recovered prior major surgery No nonapproved investigational drug within past 30 day No concurrent phenytoin , carbamazepine , barbiturate , rifampin , phenobarbital , Hypericum perforatum ( St. John 's wort )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
</DOC>